Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | GIPR | P48546 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25402556 | 0.89 | MRGPRX4 (0.47) | GCGRPTGER4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL30585066 | 0.88 | RORC (0.52) | CACNA1GCACNA1HCACNA1IMRGPRX4EGLN1 | |
| SCHEMBL25402220 | 0.88 | RORC (0.52) | CACNA1GCACNA1HCACNA1IMRGPRX4EGLN1 | |
| SCHEMBL7977921 | 0.85 | KDM4E (0.50) | PTGER4CACNA1GCACNA1HCACNA1IHDAC6 | |
| SCHEMBL6844901 | 0.85 | PTGER4 (0.46) | PTGER4HDAC6HDAC1 | |
| SCHEMBL25400692 | 0.84 | CPT1A (0.46) | CACNA1GCACNA1HCACNA1IMRGPRX4HDAC6 | |
| SCHEMBL6840441 | 0.83 | KDM5A (0.47) | PTGER4HDAC6HDAC1 | |
| SCHEMBL25402055 | 0.82 | HDAC6 (0.59) | PTGER4CACNA1GCACNA1HCACNA1IMRGPRX4 | |
| SCHEMBL25402755 | 0.81 | HCAR3 (0.49) | HDAC6 | |
| SCHEMBL25402226 | 0.81 | HDAC6 (0.49) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4494640-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212701-A | Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same | 淑明女子大学校 产学协力团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023177250-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 숙명여자대학교산학협력단 | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HDAC1, HDAC6, HDAC5 | GCGR 2721/4885PTGER4 3788/4885GIPR 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.